BIODEXA PHARMACEUTICALS-ADR (BDRX)
US59564R7089 - ADR
Posting of Annual Report & Notice of AGM - Total Voting Rights
May 15, 2024 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Posting of Annual Report & Notice of AGM Total Voting Rights Biodexa...
Biodexa’s Licensor Emtora to Announce Phase 2 Clinical Trial Results of eRapa™ in Familial Adenomatous Polyposis to be Presented at Prestigious 2024 Digestive Disease Week Annual Meeting
April 30, 2024 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa’s Licensor Emtora to Announce Phase 2 Clinical Trial Results of eRapa™ in...
Why Is Inno (INHD) Stock Up 46% Today?
Inno stock is rising higher on Monday as INHD shares experience heavy trading this morning despite a lack of news from the company.
Why Is Biodexa (BDRX) Up 70% Today?
Oncology specialist Biodexa inked a compelling licensing deal to treat a serious disease, and BDRX stock popped sharply higher.
Top movers in Friday's session
Let's have a look at what is happening on the US markets one hour before the close of the markets on Friday. Below you can find the top gainers and losers in today's session.
These stocks are the most active in today's session
These stocks are making the most noise in today's session. Stay tuned for the latest updates!
What's going on in today's session
Let's have a look at what is happening on the US markets in the middle of the day on Friday. Below you can find the top gainers and losers in today's session.
Which stocks are gapping on Friday?
Let's have a look at the gap up and gap down stocks in today's session.
Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for the Treatment of Familial Adenomatous Polyposis (FAP)
April 26, 2024 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for...
Preliminary Results for the Year Ended 31 December 2023
19 April 2024 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company” or, together with its subsidiaries, the “Group”) Preliminary Results for the Year...
Why Is Biodexa Pharmaceuticals (BDRX) Stock Up 106% Today?
Biodexa Pharmaceuticals stock is up alongside heavy trading of BDRX after announcing positive news from a brain cancer treatment trial.
Biodexa stock slides 7% amid data for two drug studies (NASDAQ:BDRX)
Shares of Biodexa (BDRX) slid 7% in morning trading Friday after the biotech company reported study results for two of its therapy candidates. Biodexa said an i
Biodexa Announces Positive Top Line Phase I Clinical Trial Results for Diffuse Midline Glioma and Provides R&D Update
Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa Announces Positive Top Line Phase I Clinical Trial Results for Diffuse Midline Glioma...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Pre-market stock movers are a hot topic on Tuesday and we're diving into all of the biggest winners and losers this morning!
Biodexa Reports 12 Month Survival in MAGIC-G1 Study of MTX110 in Recurrent Glioblastoma Patients
Biodexa Pharmaceuticals PLC Biodexa Reports 12 Month Survival in MAGIC-G1 Study of MTX110 in Recurrent Glioblastoma Patients CARDIFF, United Kingdom,...
Biodexa stock jumps on allowance of U.S. patent covering Tolimidone (NASDAQ:BDRX)
Biodexa Pharmaceuticals sees a 40% surge in premarket trading as the US Patent Office allows its patent application for Tolimidone's use in treating T1D.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Pre-market stock movers are a hot topic on Wednesday as we check out all of the biggest ones worth keeping an eye on this morning!
Biodexa CEO Issues Shareholder Letter Highlighting Progress in 2023 and Expected Milestones in 2024
Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa CEO Issues Shareholder Letter Highlighting Progress in 2023 and Expected Milestones in...
Biodexa Appoints Ann Merchant to the Board of Directors
Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa Appoints Ann Merchant to the Board of Directors CARDIFF, United Kingdom, Dec. 29, 2023...
Biodexa Announces Closing Of $6.0 Million Underwritten Public Offering, Including Full Exercise Of Overallotment Option
Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa Announces Closing Of $6.0 Million Underwritten Public Offering, Including Full Exercise Of...